omniture
logo
Search
士泽生物医药（苏州）有限公司
Media Room

Latest News

rss

XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury

SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd...

2025-07-28 21:10 2734

XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS

SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China)...

2025-06-03 09:00 1629

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shangh...

2025-05-26 09:00 2165

XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials

SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug A...

2025-04-15 21:10 2337